A sympathetic overactivity has been reported in the early stages of essential hypertension and has been involved in the pathogenesis of left ventricular hypertrophy (LVH) in essential hypertension. The state of ␤ 2 -adrenergic receptors as related to the presence of this complication was investigated in a group of 15 essential hypertensive patients and compared to 10 normotensive control subjects. Left ventricular mass index was determined by bidimensional echocardiography. Plasma catecholamine levels were measured by a radioenzymatic assay. ␤ 2 -adrenoceptor density was measured in intact lymphocytes by radioligand binding assay, using the hydrophilic ligand CGP 12177. ␤ 2 -adrenoceptor function was assessed by measuring intracellular cAMP levels in isoproterenol-stimulated lymphocytes. Left ventricular mass index (P Ͻ 0.05),
Introduction
Left ventricular hypertrophy (LVH) is a major complication in hypertension and it has been associated with an increased prevalence of life-threatening arrhythmias, coronary artery disease, heart failure and sudden death. [1] [2] [3] Therefore, LVH is considered nowadays as an independent cardiovascular risk factor. 4 Both haemodynamic and non-haemodynamic factors have been involved in the pathogenesis of this complication. An increased sympathetic activity has been described in essential hypertension, and it has been postulated that this sympathetic overactivity might be one of the nonhaemodynamic factors involved in the pathogenesis of LVH. 5 In fact, the sympathetic outflow to the heart, kidneys and skeletal muscle vasculature is commonly increased in younger patients with essential hypertension. 6 Cardiac inotropic and chronotropic responses to adrenergic stimuli have been reported to be reduced Correspondence: Dr Jordi Calls, Nephrology Unit, Fundació n Hospital de Manacor, Carretera de Manacor a Alcú dia s/n, 07500 Manacor, Mallorca, Islas Baleares, Spain Received 22 January 1999; revised 2 July 1999; accepted 23 July 1999 body mass index (P Ͻ 0.01), plasma noradrenaline levels (P Ͻ 0.05) and ␤ 2 -adrenoceptor density (P Ͻ 0.05) were higher in hypertensives than in controls. Left ventricular mass index correlated with body mass index both in normotensives and hypertensives, as well as with plasma noradrenaline levels only in normotensives. Left ventricular mass index also showed a positive correlation with mean arterial pressure and an inverse relationship with ␤ 2 -adrenoceptor density and response only in hypertensive patients. In conclusion, left ventricular hypertrophy in young essential hypertensives is associated to a reduced ␤ 2 -adrenoceptor density and function, probably as a compensating mechanism of the hypertrophied myocardiocyte secondary to the increased sympathetic outflow. Journal of Human Hypertension (2000) 14, [17] [18] [19] [20] [21] both in animal models of hypertension and hypertensive patients. 7, 8 On the other hand, several abnormalities have been reported in lymphocyte ␤ 2 -adrenoceptor characteristics in hypertensive patients, [9] [10] [11] suggesting that the same occurs in target organs, such as the heart. Interestingly, a decreased lymphocyte ␤ 2 -adrenoceptor function has been reported in essential hypertensive patients with LVH. 12 Thus, an abnormal ␤-adrenergic receptor function can be present in hypertensive patients with LVH.
The present study was designed to elucidate the relationship of the sympathetic nervous system and ␤ 2 -adrenergic receptor state in the presence of LVH in young patients with essential hypertension.
Materials and methods
Fifteen patients with mild-to-moderate uncomplicated essential hypertension (nine male and six female, mean age 38 ± 1.2 years, mean ± s.e.m.) and 10 normotensive control subjects (six male and four female, mean age 36 ± 1.3 years) of similar age and sex were included in the study. Hypertension was defined as a sitting diastolic blood pressure greater than 90 mm Hg on two separate occasions in untreated patients or at the end of a 3-week wash-Journal of Human Hypertension out period. Written informed consent was obtained from all participants and the study was approved by the Ethical Committee of our institution and conformed with the principles outlined in the Declaration of Helsinki.
Height and weight were measured in all subjects before the study. Body mass index (BMI) was calculated according to the formula: BMI = weight/height 2 . Blood pressure was determined by taking the average of three measurements with a mercury sphygmomanometer, after at least 10 min sitting at rest. Diastolic blood pressure was considered as Korotkoff phase V. Mean blood pressure (MBP) was calculated as the diastolic plus one-third of the pulse pressure. Subjects were on a sodiumfree diet and in treated hypertensive patients antihypertensive drugs were withdrawn for at least 3 weeks before the study. All subjects abstained from alcohol or caffeine for at least 12 h, refrained from smoking for at least 24 h and fasted for at least 8 h before the study. Secondary causes of hypertension were discarded in hypertensive patients by clinical, radiological, biochemical and hormonal criteria. Patients under diuretic, vasodilator, ␤-adrenergic agonist, hormonal contraception or steroid treatment were excluded. Twenty-four hour ambulatory blood pressure monitoring was performed on all subjects with a Diasys 200R monitor (Novacor, France). Patients with 'white coat hypertension' were also excluded. Subjects were placed in a supine position for 1 h before the beginning of the study, which was performed in the morning, between 9 and 10 am. A cannula was inserted in an anterocubital vein for blood sampling before the start of the study. After 1 h of rest in a supine position, a blood sample was taken for measurement of plasma catecholamines and lymphocyte ␤ 2 -adrenoceptor characteristics.
Left ventricular mass index (LVMI) determination
Left ventricular mass was determined by bidimensional Doppler-echocardiography and calculated according to the Penn's convention 13 by a cardiologist who was unaware of the situation of the subjects (hypertensives or normotensives) (observerblinded). LVMI was defined as left ventricular mass/body surface (in m 2 ).
Plasma catecholamines
Plasma catecholamine levels were measured by a radioenzymatic assay followed by a thin-layer chromatography using a commercial kit (Cat-a-kit, Amersham Lab, Amersham, UK). 14 ␤ 2 -adrenergic receptor characteristics Lymphocytes were isolated from total blood according to the Boyü m's method. 15 Lymphocyte ␤ 2 -adrenoceptor density and affinity (Kd) were determined by radioligand binding assay using the hydrophilic ligand [ 3 H]-CGP12177, as described elsewhere.
16
␤ 2 -adrenergic response was assessed by measuring the increase in intracellular cAMP levels in isoproterenol-stimulated lymphocytes, as published elsewhere. 17 
Calculations and statistics
Specific binding was calculated as the difference between total and non-specific binding. Maximum binding (B max ) and the dissociation constant (Kd) for CGP-12177 in lymphocytes were calculated from Scatchard plots 18 using the non-linear regression LIGAND computer program. 19 Maximum binding was expressed as the number of receptors per cell, and the dissociation constant (Kd) in nM. Intracellular levels of cAMP were expressed in pmol of cAMP/2.25 × 10 6 lymphocytes. Data are expressed as mean ± s.e.m. Differences between normotensives and hypertensives were analysed by means of unpaired Student's t-tests. Correlation coefficients were calculated by the least-square's method. P Ͻ 0.05 (two-sided) was considered as statistically significant.
Results
No differences with respect to age and sex were observed between normotensive subjects and hypertensive patients. Mean blood pressure, BMI, LVMI and plasma noradrenaline levels were higher in hypertensive patients than in controls (Table 1) . Hypertensive patients showed a mean lymphocyte ␤ 2 -adrenoceptor density higher than normotensive subjects, but no differences in receptor affinity (Kd) or response were observed between the two groups.
In the normotensive group, LVMI correlated with BMI (r = 0.71, P Ͻ 0.05), as well as with plasma noradrenaline levels (r = 0.78, P Ͻ 0.05). The relationship between BMI and plasma noradrenaline levels in normotensives was in the limit of the significance (r = 0.58, P Ͻ 0.1). In the hypertensive group, LVMI showed a positive correlation with age (r = 0.56, Kd, dissociation constant; Values: mean ± s.e.m. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 with respect to the normotensive group. 
Discussion
Left ventricular hypertrophy is a well recognised independent cardiovascular risk factor among patients with essential hypertension. 4 Its presence in hypertensive patients has been associated with an increased prevalence of coronary artery disease, lifethreatening arrhythmias, heart failure and sudden death. [1] [2] [3] [4] Both haemodynamic (elevated blood pressure levels) and non-haemodynamic (neurohormonal and growth factors) mechanisms have been involved in its pathogenesis. In the present study, mean blood pressure and body mass index strongly and positively correlated to left ventricular mass in hypertensive patients, suggesting a role for both high blood pressure and obesity in the pathogenesis of LVH among hypertensive patients. On the other hand, body mass index and plasma noradrenaline levels, but not blood pressure, were positively correlated to left ventricular mass index in normotensives. Since obesity is associated with an increase in sympathetic activity and plasma noradrenaline levels have shown a correlation with body mass index in the limit of the significance in normotensive subjects in our study, it is tempting to speculate that the main determinant of LVMI in normotensives is the degree of activation of the sympathetic nervous system, which in turn is related to the body mass index.
Consistent with previous studies, 20 we found that plasma noradrenaline levels were higher in hypertensive patients than in normotensive subjects, suggesting that in young patients with essential hypertension there is an activation of the sympathetic nervous system. 5 We also found that lymphocyte ␤ 2 -adrenoceptor density was increased in hypertensive patients, as previously described, [9] [10] [11] while ␤ 2 -adrenoceptor response was similar in both groups. A novel and interesting finding resulting from this study was that LVMI showed an inverse relationship with both lymphocyte ␤ 2 -adrenoceptor density and response in hypertensive patients only, suggesting that ␤-adrenoceptors are down-regulated in hypertensive patients with left ventricular hypertrophy.
Noradrenaline, the neuroeffector of the sympathetic nervous system, is one of the non-haemodynamic factors that have been involved in the development of LVH in essential hypertension. In experimental studies, LVH can be induced by subpressor doses of catecholamines. 21 Catecholamines may induce protein synthesis and cellular growth in cardiomyocytes in vitro, through an ␣ 1 -adrenoceptor-mediated mechanism. 22 Furthermore, the heterogeneous efficacy in the regression of LVH induced by different antihypertensive drugs in hypertensive patients, despite similar blood pressure decreases, may only be explained by the non-haemodynamic mechanisms involved in the pathogenesis of this complication. 23 In this sense, LVH can only be prevented if blood pressure reduction is not associated with reflex cardiac sympathetic activation. 24 From another aspect, the myocardium in experimental animal models of hypertension is known to exhibit reduced cardiac inotropic and chronotropic responses to adrenergic stimulation. 7 Even though some initial reports indicated an increased ␤ 2 -adrenergic chronotropic response in patients with essential hypertension, 25, 26 a number of recent studies have shown that cardiac ␤ 2 -adrenergic response is in fact decreased in hypertensive patients. 8, 27 The aetiology of this decreased responsiveness is probably multifactorial, but alterations in the ␤-adrenergic receptor-adenilylcyclase system appear to be a contributing factor. Studies performed in animal models of genetic and acquired hypertension have shown a desensitization of cardiac adrenergic receptors 28, 29 and that cardiac sympathetic neuronal function deteriorates in association with cardiac ␤-adrenoceptor down-regulation. 30 In humans, a reduced ␤ 2 -adrenoceptor density and response associated to LVH due to pressure overload has been observed in myocardial tissue obtained from valvereplacement interventions. 31 In vivo evaluation of human cardiac ␤ 2 -adrenoceptor density using positron emission tomography with the radioactive ligand CGP12177 has recently been developed. By using this novel technique, a reduced cardiac ␤-adrenoceptor density in patients with myocardial hypertrophy of several aetiologies, including essential hypertension, has been observed. 32 Our results, demonstrating an inverse relationship between ␤-adrenoceptor density and response and left ventricular mass index in our hypertensive patients are consistent with these previous results. In humans, lymphocyte ␤-adrenoceptor density is closely correlated with the corresponding ␤-adrenoceptor density in the right atrial appendages obtained from the same subjects, 33 thus suggesting that changes in lymphocyte ␤-adrenoceptor characteristics can be extrapolated to what happens in solid tissues, such as the heart. A decreased lymphocyte ␤ 2 -adrenoceptor density and response have been reported in patients with pheochromocytoma 17 and heart failure, 34, 35 conditions characterised by a chronic elevation of plasma catecholamines. A reduced lymphocyte ␤ 2 -adrenoceptor function in essential hypertension has been reported by Feldman et al, 28 in contrast to the initial observations of Brodde et al. 36 Furthermore, a blunted ␤-adrenoceptormediated cardiovascular response associated with increased ␤-adrenoceptor density in lymphocytes of hypertensive patients. 37 These results suggest that the increase in ␤-adrenoceptor density in essential hypertension is secondary to a decreased ␤-adrenoceptor function.
Yurenev et al 12 reported that lymphocyte ␤ 2 -adrenoceptor density was increased, while ␤ 2 -adrenoceptor response was similar, in hypertensive patients with LVH with respect to hypertensive patients without LVH and also found a positive correlation between lymphocyte ␤ 2 -adrenoceptor density and left ventricular mass, postulating that the increased density of these receptors could represent a better end-organ damage marker than blood pressure levels in essential hypertension. However, in this study plasma catecholamine levels were not determined and body mass index was not considered. Another important methodological difference with our study is that they used a lipophilic ligand, which measures both surface and internalised (non-active) receptors. Despite the higher ␤ 2 -adrenoceptor density, no differences in the ability of isoproterenol to activate adenilylcyclase were observed between normotensives and hypertensives in our study. This relative decrease in ␤ 2 -adrenoceptor response might be due to an impaired coupling of these receptors to their G protein. In this sense a specific desensitisation of left ventricular ␤-adrenoceptors independent of plasma noradrenaline levels has been reported in a model of obesity and hypertension in dogs. 38 The inverse relationship observed between left ventricular mass index and ␤ 2 -adrenoceptor density and response suggests that left ventricular hypertrophy in essential hypertension, as occurs in other diseases, is associated to a ␤ 2 -adrenoceptor down-regulation and a decreased ␤ 2 adrenoceptor function, probably as a compensating mechanism of the hypertrophied myocardiocyte, secondary to the sympathetic nervous system overactivity reported in young essential hypertensive patients.
